agilon health

Intangible assets: moderate. The partnership model with established physician groups, rising quality performance (75% of members in 4+ star plans for PY27; 4.2 consolidated stars), and clinical playbooks create relationship stickiness and some reputational edge, but these are replicable by larger platforms and integrated payors.

Switching costs: moderate. Deep integration into practice workflows, risk adjustment, and data pipelines raises migration frictions, yet groups can move to competing enablement platforms (or payor-owned models) over a multiyear cycle. Network effects: weak.

Local scale helps referral management but the platform does not benefit from classic cross‑side effects. Cost advantages: limited. Platform support costs run about 3% of revenue, indicating operating efficiency, but not a structural cost moat versus payor-owned or larger provider platforms.

Efficient scale: local market density helps but does not prevent entry; payors can steer attribution, limiting exclusivity. Moat erosion risks include: CMS model/rate changes (V28 fully in effect for 2026 and continuing in 2027), aggressive payor re‑contracting, and utilization spikes that compress medical margin.

Weighting stronger for switching costs and cost position yields a below‑average, fragile moat overall.

Intrinsic pricing power is modest because revenues are capitated and largely defined by CMS funding and negotiated percentage‑of‑premium with payors. 2026 saw constructive rate support and improved percentage‑of‑premium terms, but this is not company‑controlled pricing; leverage sits with payors and policy.

Latent pricing upside exists in better RAF capture and quality bonuses, not list‑price increases. Dependence on external rate notices and contracting cycles makes pricing power structurally limited.

Contracted capitation produces recurring revenue, but earnings are sensitive to medical cost trend, prior‑period development, star ratings, and risk adjustment. 2025 results showed negative medical margin and a gross loss; 2026 is rebounding with Q2 medical margin of $197 million and raised guidance, yet management still embeds cost trend assumptions around the low‑7% range and acknowledges utilization uncertainty.

Net membership declined due to market and payor exits designed to improve unit economics, which aids predictability but reduces scale benefits in the near term. Overall visibility is better than in 2025 but remains moderate.

Liquidity is solid with $257 million in cash, cash equivalents and marketable securities, and low debt ($32 million) at June 30, 2026. Credit facility maturity was extended to 2028, supporting flexibility.

However, trailing‑twelve‑month operating cash flow through Q2 2026 was roughly negative $72 million and, after capex, TTM free cash flow approximated negative $85 million by our calculation (H1 2026 operating cash flow −$33.6 million; H2 2025 operating cash flow about −$38.7 million; TTM capex about $12.7 million).

Balance sheet risk is low, but cash generation is not yet durable.

Positives: exiting and re‑contracting underperforming markets, reducing Part D exposure (<15%), and focusing on higher‑quality payor terms all improve future unit economics. Negatives: a large 2023 buyback ($200 million) preceded operating losses and a 1‑for‑25 reverse split in March 2026, suggesting weak timing and limited margin of safety.

Stock‑based compensation and working‑capital swings have diluted per‑share cash economics. Until sustained free cash flow arrives, repurchases or step‑ups in growth capex should be conservative.

Leadership reset: Tim O’Rourke was appointed CEO effective May 7, 2026, with former Aetna CEO Ron Williams continuing as Chair. 2026 guidance discipline and Q2 execution are encouraging, but the leadership team’s long‑term capital allocation record at agilon is still being established.

We view governance improvements and operating rigor positively, yet we need multi‑year evidence of stable medical margin and cash conversion before scoring higher.